RxDoctor Payments DataLook up a doctor →

Jae Park, MD

Hematology & Oncology · New York, NYNPI 1669593000

Payments from drug & device makers

$9,301,903in general payments, 2019–2025

Across 521 payments — averaging $17,854 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Takeda Pharmaceuticals U.S.A., Inc.$6.7M
  • Bristol Myers Squibb$753K
  • Genentech, Inc.$705K
  • Gilead$440K
  • Incyte Corporation$333K
  • Servier Bioinnovation$161K
  • plus $231K from 17 others
$5,562in research payments, 2019–2025

Across 3 payments — averaging $1854.15 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Amgen$5K
  • Novartis$628
  • Gilead$109

What the payments were for

  • Consulting fees$251,21180%
  • Speaking & faculty fees$43,83914%
  • Travel & lodging$17,4116%
  • Food & beverage$3,1121%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,301,903 in reported general payments places this provider in the 95th percentile of 967 hematology & oncology providers in New York.

See all hematology & oncology providers in New York

Medicare billing

Part B allowed, 2024
$85,600
Medicare patients
256
Services billed
697

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in New York

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →